Movement Alert｜INSILICO falls 5.11% in Regular Trading, UBS cuts rating to Neutral

Market Focus09:57

On October 23, INSILICO fell 5.11% in Regular Trading, trading at HK$34.32, with turnover of HK$149 million.

The clearest catalyst was a recent UBS downgrade to Neutral with a target price of RMB27, which appears to have directly pressured near-term sentiment.

Earlier company disclosures had been constructive: INSILICO said its multi-year AI drug discovery collaboration with Servier, with total potential value of up to $888 million, reached its first early drug discovery milestone and triggered an undisclosed milestone payment. The company also said it nominated 11 preclinical candidate compounds in the first 10 months, a record annual pipeline output. Even so, the latest trading reaction suggests the broker rating change outweighed those positives in the current session.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment